Introduction {#Sec1}
============

Worldwide, around 387 million people have *diabetes mellitus* (DM) according to the International Diabetes Federation (IDF) update of 2014. Nearly 592 million people, or 1 person in 10, are anticipated to have diabetes in 2035 \[[@CR1]\]. Diabetes is the single major cause of end-stage renal disease (ESRD) and consequent dialysis leads to a huge burden in terms of poor quality of life and economical costs \[[@CR2]\].

*Diabetic nephropathy* (DN) is an emerging clinical and public health challenge and is related with adverse outcomes including ESRD and heart failure, as well as kidney replacement therapy \[[@CR3], [@CR4]\], deaths related to these terminal illnesses \[[@CR5], [@CR6]\] by compromising life expectancy \[[@CR7]\] in most African countries in particular \[[@CR3], [@CR4]\]. Indeed, DN remains higher in African, Asians, and Native Americans as compared to Caucasians \[[@CR8], [@CR9]\]. Generally for the past two decades, the prevalence of DN in people with diabetes has not improved because of an increase in the prevalence of reduced eGFR \[[@CR10]\]. Likewise, the magnitude of ESRD in DM patients decline faintly \[[@CR11]\] and the rate of DN increase is significant perhaps due to higher rates of type 1 and type 2 DM \[[@CR12], [@CR13]\]. In Africa, the highest magnitude of DN is associated with late diagnosis, scarcity of screening and diagnostic resources, poor control of blood sugar and other precipitating factors, and inappropriate treatment \[[@CR14]--[@CR16]\].

Various factors may be associated with a worsening renal disease among diabetic patients. Some of the major factors include genetic predisposition \[[@CR17], [@CR18]\], improper control of blood sugar \[[@CR19], [@CR20]\] and hypertension \[[@CR21], [@CR22]\]. There is evidence that both diabetes mellitus and hypertension are extremely interconnected, and in majority of the cases cardiac consequence may be associated with advanced stages of DN. For example, the relationship between hypertension and DN can be explained by the retention of concentrated sodium and subsidiary blood vessel resistance \[[@CR23]\]. Saying this, previous studies of the magnitude of DN are remains inconsistent and unclear. Furthermore, to our knowledge, there is no synthesis of existing contemporary evidence on the association between DN and hypertension in diabetic patients. Thus, the aim of this meta-analysis is to estimate the prevalence of DN and examine its association with hypertension among diabetic patients in sub-Saharan African countries.

Main text {#Sec2}
=========

Methods {#Sec3}
-------

### Search strategy and study design {#Sec4}

Using computerized databases, searches were performed to locate all studies on the prevalence of DN among diabetic patients in sub-Saharan countries. Databases included from EMBASE, Cumulative Index to Nursing and Allied Health Literature (CINHAL), Pub Med, MEDLINE, Google scholar and Google for grey literature. We extended our search by retrieving reference lists of eligible articles, hand searches for grey literature and other relevant literature collections. Observational studies conducted on the prevalence of DN among diabetic patients in sub-Saharan countries were selected for this meta-analysis. Search protocol was formulated by using such common key words as 'Renal disease OR Renal insufficiency OR Diabetic nephropathy' OR 'DN' OR end stage kidney failure, OR microalbuminuria AND hypertension OR HTN AND diabetes OR diabetes mellitus OR type 1 diabetes OR type 1 DM OR type 2 DM AND 'sub-Saharan African countries (48 countries). We exhaustively searched by using the above key words in each sub-Saharan country, for instance, in Ethiopia, Botswana, Kenya and E.T.C. To make a certain scientific rigor, we strictly followed the preferred reporting of systematic reviews and meta-analysis (PRISMA) guideline \[[@CR24]\].

### Inclusion criteria {#Sec5}

The study inclusion criteria included the following: those studies published in English, where the process of identifying DN was well described, and those studies with sufficient information to estimate the point prevalence of DN. The process of study inclusion is shown in Additional file [1](#MOESM1){ref-type="media"}: Fig. S1.

### Exclusion criteria {#Sec6}

Available studies were excluded if only the DN incidence in follow-up years was reported or when they did not explain the process/criteria of DN diagnosis and inability to access full-text.

### Data extraction {#Sec7}

All identified studies were screened for inclusion by two reviewers (FW and GDK). Discussions and mutual consensus were in place when possible arguments were raised between the two reviewers. These reviewers then assessed the full text of potentially eligible papers. We made some efforts to communicate primary authors whenever further information was needed. Numerator and denominator data and beta coefficients and their standard errors (if given) were used to calculate ORs, where ORs with 95% CI were not given. The data extraction format included first author, study year, region of study, study design, sample size, diagnostic criteria and types of diabetes. The occurrence of DN and HTN were also extracted from each included study.

### Quality appraisal {#Sec8}

The included articles were evaluated for quality, with only high quality studies included in the analysis. Two authors (FW, GDK) independently assessed the quality of each included paper. The reviewers compared their quality appraisal scores and resolved any disparity before calculating the final appraisal score. Newcastle--Ottawa Scale adapted for cross-sectional studies quality assessment tool was used \[[@CR25]\]. The tool has three sections in general; the first section graded from five stars and due emphasis on the methodological quality of each original study. The second section of the tool explains with the comparability of the study. The third section focus on the outcome and statistical analysis of each original study. Articles with a scale of ≥ 6 out of 10 scales were considered as high quality. Consequently, all eligible studies had high quality scores.

### Data analysis {#Sec9}

Information about the study design, study sample, etc. were summarized by Microsoft excel. Relevant data were then exported to STATA/se version 14 software for analysis. Meta-analysis of pooled prevalence of DN was carried out using a random-effects model, generating a pooled prevalence with 95% CIs, by using the approach of DerSimonian and Laird statistical method \[[@CR26]\]. Heterogeneity among studies was estimated using the Cochran's Q and I^2^ statistic and is characterized as low, moderate, or high for 25%, 50%, and 75%, respectively \[[@CR27]\]. We also scrutinized forest plots of summary estimates of each study to determine whether we could identify any outlier or heterogeneity. Publication bias was determined based on the symmetry of funnel plots \[[@CR28]\], and Egger's test \[[@CR29]\]. Sub-group analyses were carried out by region, sample size and types of DM for there was significant heterogeneity across the included studies.

Results {#Sec10}
-------

### Flow chart {#Sec11}

Figure [1](#Fig1){ref-type="fig"} shows the flow chart and selection process of exploring the prevalence of DN among DM patients. Our electronic database search offered 1766 articles, of those 1545 non-duplicate papers were assessed and 1496 excluded after reviewing their title and abstracts.Fig. 1Pooled prevalence of DN among DM patients in sub-Saharan countries

The remaining 49 were examined by full text. Of which, 22 articles were excluded due to unmet outcome of interest; only 27 studies met our inclusion criteria. The characteristics and quality assessment of all included studies are shown in Table [1](#Tab1){ref-type="table"}. Five studies reported odds ratios of the odds of hypertension in diabetic patients. *Finally*, 27 articles representing 6552 participants met the inclusion criteria (Additional file [1](#MOESM1){ref-type="media"}: Fig. S1).Table 1Characteristics of included studies to determine the prevalence of DN and association with hypertension among diabetic patients in sub-Saharan countriesAuthors nameRegionCountryDiagnostic criteriaTypes of DMStudy designAge of subjectsSample sizeNo of people with outcomePrevalence (%)Rahlenbech \[[@CR43]\]Eastern AfricaEthiopiaMicroalbuminuriaBoth typesCross-sectional≥ 181705532.35Sobngwi et al. \[[@CR44]\]Central AfricaCameroonMicroalbuminuriaBoth typesCross-sectional≥ 18643453.13Motala et al. \[[@CR45]\]Southern AfricaSouth AfricaProteinuriaBoth typesCross-sectionalAll2195424.66Wanjohi et al. \[[@CR46]\]Eastern AfricaKenyaAlbuminuriaType 2Cross-sectional≥ 181002626.00Rotchford and Rotchford \[[@CR31]\]Southern AfricaSouth AfricaMicroalbuminuriaBoth typesCross-sectional≥ 1825410240.16Albiosu \[[@CR47]\]Western AfricaNigeriaMicroalbuminuriaBoth typesCross-sectional≥ 183429728.36Alebiosu et al. \[[@CR48]\]Western AfricaNigeriaAny signBoth typesCross-sectionalNot report46519141.08Agaba et al. \[[@CR49]\]Western AfricaNigeriaMicroalbuminuriaType-2Cross-sectional≥ 18653249.23Mafundikwa et al. \[[@CR50]\]Eastern AfricaZimbabweProteinuriaType-2Cross-sectional≥ 18751621.33Lutale et al. \[[@CR51]\]Eastern AfricaTanzaniaMicroalbuminuriaBoth typesCross-sectionalAll age2442610.66Majaliiwa et al. \[[@CR52]\]Eastern AfricaTanzaniaMicroalbuminuriaType-1Cross-sectional\< 18992929.29Rahamtalla et al. \[[@CR53]\]Eastern AfricaSudanNephropathyType-2Cross-sectional≥ 18582644.83Rasmussen et al. \[[@CR54]\]Eastern AfricaZambiaMicroalbuminuriaNot-reportCross-sectional\< 181932412.44Tamba et al. \[[@CR55]\]Central AfricaCameroonNephropathyType-2Cross-sectional≥ 181403525.00Janmohamed et al. \[[@CR56]\]Eastern AfricaTanzaniaeGFRBoth typesCross-sectional≥ 1836930883.47Ajayi et al. \[[@CR57]\]Western AfricaNigeriaeGFRType 2Cross-sectional≥ 1862824238.54Deribe et al. \[[@CR58]\]Eastern AfricaEthiopiaeGFRNot reportCross-sectional≥ 18216198.80Fiseha et al. \[[@CR59]\]Eastern AfricaEthiopiaeGFRBoth typesCross-sectional≥ 182145123.83Bunza et al. \[[@CR60]\]Western AfricaNigeriaNephropathyBoth typesCross-sectional≥ 181002222.00Ngassa et al. \[[@CR61]\]Southern AfricaSouth AfricaMicroalbuminuriaBoth typesCross-sectional≥ 1875425133.29Diouf et al. \[[@CR62]\]Western AfricaSenegalMicroalbuminuriaType-2Cross-sectional≥ 181959548.72Chukwuani et al. \[[@CR63]\]Western AfricaNigeriaMicroalbuminuriaType-2Cross-sectional≥ 182007638.00Bekele \[[@CR64]\]Eastern AfricaEthiopiaNephropathyBoth typesCross-sectional≥ 183556819.15Ufuoma et al. \[[@CR65]\]Western AfricaNigeriaMicroalbuminuriaType-2Cross-sectional≥ 1820011658.00Machinngura et al. \[[@CR66]\]Eastern AfricaZimbabweNephropathyBoth typesCross-sectional≥ 1834415444.77Radikara \[[@CR67]\]Southern AfricaBotswanaNephropathyType-2Cross-sectional≥ 1840825963.48Marie et al. \[[@CR30]\]Central AfricaCameroonMicroalbuminuriaNot reportCross-sectional≥ 18812834.57

### Characteristics of included studies {#Sec12}

A total of 6552 participants were represented by 27 included studies (Table [1](#Tab1){ref-type="table"}), published from 1997 to 2017. Ten studies (37%) reported the prevalence of DN among type-2 diabetic patients. Three studies (11.1%) included all age groups (both children and adults); study exclusively assessed DN among type-1 DM (Table [1](#Tab1){ref-type="table"}).

Five studies included determined the effect of hypertension on diabetic nephropathy. These studies reported ORs between 1.4 \[[@CR30]\] and 2.11 \[[@CR31]\] for the rate of hypertension leading to DN (Additional file [2](#MOESM2){ref-type="media"}: Table S1).

### Meta-analysis {#Sec13}

As presented in the forest plot (Fig. [1](#Fig1){ref-type="fig"}), the pooled prevalence of DN among diagnosed DM cases was 35.3 (95% CI 27.46--43.14). The I^2^ test result indicated high heterogeneity (I^2^ 98.2%, p \< 0.001). Thus, a subgroup analysis was done.

Our meta-analysis of the association between DN and hypertension included five studies, all of which reported ORs explicitly. Pooled point estimates from cross-sectional studies showed an increased risk of DN with hypertension compared without hypertension (OR = 1.67, 95% CI 1.31, 2.14). Overall heterogeneity of these studies was not significant (I^2^ = 0.0%, p = 0.79) (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Pooled odds ratio indicating the association of hypertension with DN in diabetic patients

Discussion {#Sec14}
----------

DN is becoming universal cause of ESRD and is recognized as an independent risk factor for cardiovascular disease \[[@CR32]\]. Once elevated urinary albumin excretion, it may be inevitable to end with the development of nephropathy, though it may be possible to significantly hinder its development at early stages of the disease. The roles of glucose and blood pressure control may suffice here.

As shown in Additional file [3](#MOESM3){ref-type="media"}: Fig. S2, the burden of DN in diabetic patients has been significantly increased from 2015 to 2017. Therefore it needs special attention devotion to minimize the occurrence of the disease.

To our knowledge, this is the first pooled analysis of the prevalence of DN and its association with hypertension in sub-Saharan African countries. Existing evidence from included studies suggest that DN is high among diabetic patients in sub-Saharan countries. It is a study done by Stanford A \[[@CR33]\] that revealed adults with type-2DM (n = 2006), with 38.3% having had DN during 2007--2012. Likewise, of the 5072 confirmed diabetes diagnosis, 31% had clinically significant DN, (D2) with microalbuminuria of 31.6 (95% CI 30.6--32.6) \[[@CR34]\]. On the other hand, this finding is higher as compared to previous systematic review and meta-analysis done by Elhafeez et al. \[[@CR35]\] reporting 24.7% (95% CI 23.6--25.7%) pooled prevalence of DN among diabetic patients \[[@CR35]\]. This discrepancy attributed to differences in some factors including study period, sociodemographic characteristics, diagnostic criteria, as well as the methods of measurement of proteinuria and urine collection, diabetic type and duration and varying prevalence of hypertension across studies might contribute for the difference.

We did sub-group analysis due to a significant high heterogeneity. As showed in Additional file [4](#MOESM4){ref-type="media"}: Table S2, the prevalence of DN was higher in type-2 DM \[41.39% (95% CI 32.2--50.6)\] and Southern Africa \[40.4% (95% CI 24.1--56.7)\], correspondingly (Additional file [4](#MOESM4){ref-type="media"}: Table S2).

This study also revealed that hypertension significantly increased the occurrence of DN among people who have a diagnosis of DM. This finding supported by study done Wu B showed that hypertension is a major factors associated with CKD among diabetes patients (OR = 1.78) \[[@CR33]\]. Likewise, another study revealed that hypertension is considered to pivotal role for the occurrence of DN \[[@CR36]\]. Furthermore, the association between increased blood pressure and DN was recognized by most of the previous studies \[[@CR37]--[@CR39]\]. This could be due to oxidative stress and inflammation process. That is, the evidence suggests local generation of oxidative stress and inflammation is common mechanism in DN pathogenesis in the presence of hypertension and DM. Furthermore, hypertension induced increased intra-glomerular pressure leads to glomerular sclerosis and different renal diseases \[[@CR40]--[@CR42]\].

The overall Egger's test for publication bias revealed no statistically significant evidence, *p* value = 0.08.

Conclusion {#Sec15}
----------

DN is an ordinary complication in diabetic patients where pooled point estimates showing an increased risk of DN with hypertension. We recommend that a multifactorial approach, including lifestyle modification, Early detection of microalbuminuria, blood glucose control, blood pressure normalization, and the use of treatment that hold up with the RAS (Rennin Angiotensin System) and oxidative stress.

Limitations {#Sec16}
===========

However, the findings need to be considered in the context of some important limitations. These include the inclusion of studies published only in English that may cause language bias. Furthermore, due to significant heterogeneity across studies, this study did not determine other possible risk factors contributing for the occurrence of DN in DM patients.

Additional files
================

 {#Sec17}

**Additional file 1: Fig. S1.** Flow chart describing selection of studies for a meta-analysis of the prevalence of DN and association hypertension among diabetic patients in sub-Saharan Africa. **Additional file 2: Table S1.** The effect of hypertension on diabetic nephropathy among diabetes patients. **Additional file 3: Fig. S2.** Time trend of DN in sub-Saharan countries from 1997 to 2017. **Additional file 4: Table S2.** Subgroup analysis based on region, types of diabetes and sample size among diabetes patients.
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